

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Cancelled)

2 (Previously Presented). A peptide according to claim 25, wherein the hydrophobic amino acid residue is selected from the group of residues consisting of Leu, Ile, Val, Phe, Tyr, Nle and Nva.

3 (Previously Presented). A peptide according to claim 25(C), wherein the peptide is elongated by additional amino acid residues at the N-terminal.

4 (Previously Presented). A peptide according to claim 3, wherein the additional amino acid residues constitute sequences of the human CRP.

5 (Previously Presented). An N-acyl peptide according to claim 25(D), wherein acyl is a radical R-X-CO-, wherein R is substituted or unsubstituted hydrocarbyl and X is a covalent bond, O, NH, or NHCO.

6 (Previously Presented). An N-acyl peptide according to claim 5, wherein R is optionally substituted alkanoyl or aroyl.

7 (Previously Presented). An N-acyl peptide according to claim 6, wherein the acyl radical is selected from

Appln. No. 09/1~~1~~,380

Amdt. dated October 29, 2003

Reply to Office action of July 29, 2003

octanoyl, monomethoxysuccinyl, carbobenzoxy (benzyl-O-CO-), acetylaminocaproyl, Fmoc (fluorenylmethoxycarbonyl), naphthyl-NH-CO- and adamantlyl-NH-CO.

8 (Previously Presented). A peptide according to claim 25, selected from the group of sequences consisting of:

Val-Thr-Val-Ala-Pro-Val-His-Ile (residues 89-96 of SEQ ID NO:3)

Val-Thr-Val-Ala-Pro-Val-(D)His-Ile

Val-Thr-Val-Ala-Pro-(D)Val-His-Ile

Val-Thr-Val-Ala-Pro-(D)Val-(D)His-Ile

Val-Thr-Val-Ala-Pro-Val-Ser-Ile (SEQ ID NO:8)

Val-Thr-Val-Ala-Pro-Val-Phe-Ile (SEQ ID NO:9)

Val-Thr-Val-Ala-Pro-Val-His-Ile-NH₂ (SEQ ID NO:13)

Val-Thr-Val-Ala-Pro-Val-His-Ile-Pro-NH₂ (SEQ ID NO:10)

Val-Thr-Val-Ala-Pro-Phe-His-Ile-Pro-NH₂ (SEQ ID NO:11)

Val-Thr-Val-Ala-Pro-Val-His-Ile-Pro-Pro-NH₂ (SEQ ID NO:12)

MeOSuc-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:13)

MeOSuc-Phe-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:14)

Octanoyl-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:13)

Appln. No. 09/111,380
Amtd. dated October 29, 2003
Reply to Office action of July 29, 2003

Acetylaminocaproyl-Val-Thr-Val-Ala-Pro-Val-His-Ile

(SEQ ID NO:13)

AdamantylNH-CO-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ
ID NO:13)

α -Naphthyl-NH-CO-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ
ID NO:13)

CBz-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:13)

CBz-Phe-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID
NO:14)

Fmoc-Val-Thr-Val-Ala-Pro-Val-His-Ile (SEQ ID NO:13)

wherein CBz is carbobenzoxy, MeOSuc is
monomethoxysuccinyl and Fmoc is 9-fluorenylmethoxycarbonyl.

9 (Previously Presented). A pharmaceutical
composition comprising a CRP-derived peptide according to claim
25, and a pharmaceutically acceptable carrier.

10-11 (Cancelled)

12 (Previously Presented). A method for the
treatment of a chronic inflammatory condition which comprises
administering to a patient in need thereof an effective amount
of a peptide according to claim 25.

13 (Previously Presented). A method according to
claim 12, wherein the chronic inflammatory condition is
rheumatoid arthritis, pulmonary emphysema or cystic fibrosis.

14-24 (Cancelled)

25 (Currently Amended). An isolated peptide capable of inhibiting *in vitro* the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG), said peptide being:

(A) a core peptide identical to positions 89-96 of the sequence of human C-reactive protein (CRP) of the formula:

Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3);

(B) a modification of (A) in which one or more of the following additional modifications is optionally made:

(i) substitution of Ile₉₆ by a hydrophobic amino acid residue;

(ii) substitution of His₉₅ by Asp, Glu, Ser, Thr, Phe, or Tyr, an N-alkyl derivative of His, Asp, Glu, Ser, Thr, Phe or Tyr, or a D-form of His, Asp, Glu, Ser, Thr, Phe or Tyr;

(iii) substitution of Val₉₄ by Ala, His or Phe, or a D-form of Val, Ala, His or Phe;

(iv) substitution of Ala₉₂ by a hydrophobic amino acid residue;

(v) substitution of Val₉₁ by Ala or Gly;

(vi) substitution of Thr₉₀ by Asn, Asp, Gln, Glu, Ala, Val or Pro; and

(vii) substitution of Val₈₉ by a hydrophobic amino acid residue;

with the proviso that the residue at 89 is not Leu, the residue at 90 is not Glu, the residue at 91 is not Ala, the residue at 92 is not Ile, the residue at 94 is not Ala or Val or Phe, the residue at 95 is not Ser, and the residue at 96 is not Ile, all at the same time;

(C) a peptide obtained by elongation of (A) or (B) at the N- and/or C-terminal, but not including the entire CRP; or

(D) an amide of the C-terminal of (A), (B), or (C), and/or an N-acyl derivative of (A), (B), or (C).

26 (New). A peptide according to claim 25, wherein the peptide of (C) is no longer than 30 residues.